MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New option for treating type 2 diabetes

Back to diabetes watch blog Blogs list Cancer blog  


Subscribe To Diabetes Watch Blog RSS Feed  RSS content feed What is RSS feed?

New option for treating type 2 diabetes




New option for treating type 2 diabetes
A review of prior studies indicates that use of a class of medications known as incretin-based treatment, which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the therapy of type 2 diabetes and may represent an alternative to other hypoglycemic therapies, as per an article in the July 11 issue of JAMA.

Current therapies for type 2 diabetes are often limited by adverse effects such as weight gain or hypoglycemia (low blood sugar). A more recent class of therapy to address these issues is incretin treatment, which involves glucose-stimulated insulin secretion by intestinally derived peptides, which are released in the presence of glucose or nutrients in the gut, as per background information in the article. In October 2006 the Food and Drug Administration approved the first oral incretin enhancer, sitagliptin, a selective DPP4 inhibitor (a class of oral hypoglycemics), for use as monotherapy or in combination with other medications. The effectiveness of this class of medications in managing type 2 diabetes is not well understood.

Renee E. Amori, M.D., of Tufts-New England Medical Center, Boston, and his colleagues conducted a meta-analysis of 29 studies to assess the effectiveness and safety of incretin-based treatment (GLP-1 analogues and DPP4 inhibitors) in nonpregnant adults with type 2 diabetes.

Our analysis of randomized controlled trials showed that incretin-based treatment with GLP-1 analogues or DPP4 inhibitors in adults with type 2 diabetes is moderately effective in improving glycemia, with greater reductions in postprandial [after a meal] glycemia and favorable (GLP-1 analogues) or neutral (DPP4 inhibitors) effects on weight. Glucagon [a hormone secreted by the pancreas]-like peptide 1 analogues were linked to gastrointestinal adverse effects, while DPP4 inhibitors had a slightly increased risk of infection (nasopharyngitis [inflammation of the nasal passages] and urinary tract infection) and headache, the authors write.

Incretin treatment offers an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 diabetes with modest efficacy and a favorable weight change profile, they write. Individuals with mild diabetes, suggesting an adequate pancreatic beta cell reserve, who are at risk of hypoglycemic sequelae and in need of weight loss may benefit from this new class. However, these new classes of hypoglycemic agents will need continued evaluation both in long-term efficacy and safety controlled trials and in clinical practice to assess their effectiveness and safety profile to determine their role among the a number of available and well-established therapies for type 2 diabetes.


Posted by: JoAnn    Source




Did you know?
A review of prior studies indicates that use of a class of medications known as incretin-based treatment, which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the therapy of type 2 diabetes and may represent an alternative to other hypoglycemic therapies, as per an article in the July 11 issue of JAMA.

Medicineworld.org: New option for treating type 2 diabetes

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.